ArticleNeuron2025
The polypharmacology of psychedelics reveals multiple targets for potential therapeutics.
Abstract read
In one paragraph
Article in Neuron, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Neuroplastic white matter changes in patients with major depression following lysergic acid diethylamide treatment.Cell reports. Medicine · 2026Trial
- Serotonin biology as a basis for explaining psychedelic drug action.Current biology : CB · 2026Review
- Psilocybin produces amplified acute responses and sex-specific long-term increases in sensorimotor gating in the mGlu5 knockout mouse model of schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Moving beyond 5-HTPsychopharmacology · 2026Article
- Deconstruction of lysergic acid diethylamide.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Structure-based design of subtype-selective psychedelic analogs.Nature communications · 2026Article
- Mechanistic Basis for 5-HTNature communications · 2026Article
- The Emergence of Isotryptamine Analogs as Novel Serotonergic Agents with Psychotherapeutic Potential.ACS pharmacology & translational science · 2026Review
- Global perspectives on central nervous system drug innovation: achievements, barriers, and priorities for the next decade.The international journal of neuropsychopharmacology · 2026Review
- Role of β-Arrestin2 Signaling in Neuropharmacological Effects of Psychedelic Drugs.ACS chemical neuroscience · 2026Article
- High-sensitivity immunochromatographic assay based on time-resolved fluorescence microspheres for the simultaneous detection of mescaline and LSD in hair.Analytical and bioanalytical chemistry · 2026Article
- Classic Psychedelics for Treating Chronic Pain: Mechanism and Clinical Translation.Molecules (Basel, Switzerland) · 2026Review
- Psychedelic drug action at dendrites is gated by behavioral state and serotonin receptors.bioRxiv : the preprint server for biology · 2026Article
- Integrated 5-HTMolecular psychiatry · 2026Article
- Psychedelics produce enduring enhancement of reward responsiveness in male rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- The working lives of neuronal 5-HTRSC chemical biology · 2026Review
- αMolecular psychiatry · 2026Article
- Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit-Risk Considerations in Policy and Clinical Development.Biomolecules · 2026Review
- The Emerging Neurobiology of Psychedelics: Critical Periods, Metaplasticity, and Extracellular Matrix Remodeling.Annual review of neuroscience · 2026Review
- No evidence for direct physical interaction of 5-HTbioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Manish K Jain *Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7365, USA.
Ryan H Gumpper *Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7365, USA.
Samuel T Slocum *Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7365, USA.
Gavin P Schmitz *Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7365, USA.
Jakob S MadsenDepartment of Drug Design and Pharmacology, University of Copenhagen, 2100 Copenhagen, Denmark.
Tia A TumminoDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA 94158, USA.
Carl-Mikael SuomivuoriDepartment of Computer Science, Stanford University, Stanford, CA 94305, USA; Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94304, USA; Department of Structural Biology, Stanford University School of Medicine, Stanford, CA 94305, USA; Institute for Computational and Mathematical Engineering, Stanford University, Stanford, CA 94305, USA.
Xi-Ping HuangNational Institute of Mental Health Psychoactive Drug Screening Program, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7365, USA.
Laura ShubInstitute of Neurodegenerative Diseases, University of California, San Francisco, San Francisco, CA 94158, USA.
Jeffrey F DiBertoDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7365, USA.
Kuglae KimDepartment of System Biology, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, South Korea.
Chelsea DeLeonDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7365, USA.
Brain E KrummDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7365, USA.
Jonathan F FayDepartment of Biochemistry and Molecular Biology, School of Medicine, University of Maryland, Baltimore, MD 21201, USA.
Michael KeiserInstitute of Neurodegenerative Diseases, University of California, San Francisco, San Francisco, CA 94158, USA.
Alexander S HauserDepartment of Drug Design and Pharmacology, University of Copenhagen, 2100 Copenhagen, Denmark.
Ron O DrorDepartment of Computer Science, Stanford University, Stanford, CA 94305, USA; Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94304, USA; Department of Structural Biology, Stanford University School of Medicine, Stanford, CA 94305, USA; Institute for Computational and Mathematical Engineering, Stanford University, Stanford, CA 94305, USA.
Brian ShoichetDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA 94158, USA.
David E GloriamDepartment of Drug Design and Pharmacology, University of Copenhagen, 2100 Copenhagen, Denmark.
David E NicholsDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7365, USA.
Bryan L RothDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7365, USA; National Institute of Mental Health Psychoactive Drug Screening Program, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7365, USA; Divison of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7360, USA. Electronic address: bryan_roth@med.unc.edu.
Funding
Mechanistic insights into LSD actions at 5-HT2A serotonin receptorsR37DA045657 · NIDA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Bryan L. Roth · 2018 to 2026
$5.8MNIDA NIH HHS R37 DA045657
Abstract
The classical psychedelics (+)-lysergic acid diethylamide (LSD), psilocybin, and mescaline exert their psychedelic effects via activation of the 5-HT
Indexed as
HallucinogensPolypharmacologyReceptors, G-Protein-CoupledAnimalsHumansLysergic Acid DiethylamideReceptor, Serotonin, 5-HT2ATryptaminesHallucinogensLysergic Acid DiethylamideReceptor, Serotonin, 5-HT2AReceptors, G-Protein-CoupledTryptaminesdopamine receptorsG-protein-coupled receptorshallucinogenpsychedelicsserotonin receptors
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.